CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, haematopoiesis, inflammation and response to bacterial infection. Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases. Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signalling pathways promoting calcium mobilisation and actin-mediated cytoskeleton reorganisation essential for cell migration and adhesion. Upon interaction with LGALS9 ligand, activates downstream signalling components including LCK, ERK and MAPK to promotes NK cell activation. Location: Cell membrane; Cell projection, microvillus; Secreted (UniProt). Locus 11p13 (HGNC).
- Gastric & gastro-oesophageal junction cancer: CIViC evidence names this disease
- Ovarian cancer: CIViC evidence names this disease
- Colorectal cancer: CIViC evidence names this disease
- Head and neck squamous cell carcinoma: CIViC evidence names this disease
- Prostate cancer: CIViC evidence names this disease
- Bladder & urothelial cancer: CIViC evidence names this disease
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"CD44" OR ABSTRACT:"CD44" OR TITLE:"CD44 molecule IN blood group" OR ABSTRACT:"CD44 molecule IN blood group" OR TITLE:"CD44 antigen" OR ABSTRACT:"CD44 antigen" OR TITLE:"MC56" OR ABSTRACT:"MC56" OR TITLE:"Pgp1" OR ABSTRACT:"Pgp1" OR TITLE:"PGP-1" OR ABSTRACT:"PGP-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD44, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd44.json. Licence CC BY-NC 4.0.